1. Home
  2. XPEL vs HROW Comparison

XPEL vs HROW Comparison

Compare XPEL & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XPEL Inc.

XPEL

XPEL Inc.

N/A

Current Price

$38.07

Market Cap

1.3B

Sector

Industrials

ML Signal

N/A

HROW

Harrow Inc.

N/A

Current Price

$27.63

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XPEL
HROW
Founded
1999
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.0B
IPO Year
2019
2008

Fundamental Metrics

Financial Performance
Metric
XPEL
HROW
Price
$38.07
$27.63
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
9
Target Price
$57.00
★ $63.00
AVG Volume (30 Days)
251.8K
★ 544.1K
Earning Date
11-04-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
12.12
★ 71.43
EPS
★ 1.62
N/A
Revenue
★ $476,200,000.00
N/A
Revenue This Year
$11.71
$28.41
Revenue Next Year
$10.64
$58.14
P/E Ratio
$23.75
★ N/A
Revenue Growth
★ 13.27
N/A
52 Week Low
$36.99
$25.76
52 Week High
$55.91
$54.98

Technical Indicators

Market Signals
Indicator
XPEL
HROW
Relative Strength Index (RSI) 28.90 41.61
Support Level $36.99 $26.96
Resistance Level $46.97 $30.28
Average True Range (ATR) 2.12 1.31
MACD -0.56 0.07
Stochastic Oscillator 0.28 41.37

Price Performance

Historical Comparison
XPEL
HROW

About XPEL XPEL Inc.

XPEL Inc is a supplier of protective films, coatings, and related services principally to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from Product, which includes Paint protection film and Window film. The company derives revenue from Service, which includes Software, Cutbank credits, and Installation labor. The majority of revenue is derived from the United States.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Share on Social Networks: